Annovis Bio Inc. (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company focused on neurodegenerative diseases, has announced it will host a corporate update webinar on Sept. 2, 2026, at 4 p.m. EDT. The webinar will feature founder, President and CEO Maria Maccecchini, Ph.D., who will discuss recent progress, ongoing clinical programs, and upcoming milestones, including the fully enrolled pivotal Phase 3 Alzheimer's disease (AD) trial, with top-line data and regulatory submissions expected in 2027. This announcement is significant as it provides a clear timeline for potential regulatory actions that could impact the treatment landscape for Alzheimer's and Parkinson's diseases.
The company also plans to begin enrolling patients in an AD open-label study in October 2026 to generate long-term safety data, while its Parkinson's disease (PD) open-label study is already underway. Additionally, discussions are ongoing regarding the initiation of a Parkinson's disease dementia program. These developments highlight Annovis's commitment to expanding its clinical pipeline and addressing unmet medical needs in neurodegeneration.
Buntanetap, the company's lead drug candidate, is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. The potential approval of buntanetap could offer a novel therapeutic approach for millions of patients suffering from these debilitating conditions.
The webinar is expected to provide investors and stakeholders with a comprehensive overview of the company's strategic direction and near-term catalysts. Given the high unmet need for effective disease-modifying therapies in Alzheimer's and Parkinson's, the outcomes of these trials could have significant implications for the field. Annovis's progress in advancing buntanetap through late-stage development positions the company as a key player in the neurodegeneration space.
For more information about the webinar and to access the full press release, interested parties can visit https://ibn.fm/mls3F. Additional updates and news regarding Annovis Bio are available in the company's newsroom at https://ibn.fm/ANVS.
